Study S000437

Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT01107717
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 318
Start: 2009-01
Primary completion: 2023-02-03
Lead sponsor: The University of Texas Health Science Center at San Antonio
Conditions: Diabetes
Interventions: DRUG:metformin\pioglitazone\exenatide; DRUG:metformin, glyburide and glargine
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: NIH:5R01DK103841-03

Registered primary outcomes

HbA1c Level [at the end of the study (3 years)]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017285	Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study. Abdul-Ghani M, BMJ open diabetes research & care	2025	Other trial	PMID 40288809 DOI	cites ClinicalTrials.gov:NCT01107717; registry reference DERIVED:40288809
R0026084	Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Abdul-Ghani M, Diabetes care	2021	Randomized trial	PMID 33273042 DOI	cites ClinicalTrials.gov:NCT01107717; registry reference RESULT:33273042
R0052839	1047 Changes in Liver Fibrosis Scores in Patients With New Onset Type 2 Diabetes on Triple Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy: Year Two Results Olga Lavrynenko, The American Journal of Gastroenterology	2019	Randomized trial	DOI	cites ClinicalTrials.gov:NCT01107717
R0048002	Metformin/Pioglitazone/Exenatide Triple Therapy Superior to Stepwise Add-On Conventional Therapy in Newly Diagnosed Type 2 Diabetes Mabel Korsah Cunningham, MD Conference Express	2013	Randomized trial	DOI	cites ClinicalTrials.gov:NCT01107717